Investing in the future treatment of chronic refractory diseases

Santero is building a platform with the potential to transform outcomes for millions of patients living with chronic refractory infections that current therapies cannot resolve. Our lead programme targets a validated $5 billion+ market with a clear regulatory path and growing clinical urgency.

The company has raised over €10 million to date from a syndicate of leading life sciences investors and public funding bodies, and is currently advancing towards its next round of financing to fund IND-enabling studies.

For more information on partnering or investment opportunities, please contact us.